<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938756</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000633542</org_study_id>
    <secondary_id>COL-MENINCA</secondary_id>
    <secondary_id>COL-IDRCB-2008-A00185-50</secondary_id>
    <secondary_id>COL-0801</secondary_id>
    <secondary_id>INCA-RECF0807</secondary_id>
    <nct_id>NCT00938756</nct_id>
  </id_info>
  <brief_title>Study of Cerebrospinal Fluid Samples in Diagnosing Carcinomatous Meningitis in Patients With Cancer or Meningeal Syndrome</brief_title>
  <official_title>Interest of the Dosage of CA 15-3 in CSF for Diagnosing Carcinomatous Meningitis in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer or meningeal
      syndrome may help doctors identify biomarkers related to cancer.

      PURPOSE: This clinical trial is studying cerebrospinal fluid samples in diagnosing
      carcinomatous meningitis in patients with cancer or meningeal syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Evaluate the validity of determining CA 15-3 levels in the cerebrospinal fluid (CSF)
           using automated immuno-enzymatic methods.

      Secondary

        -  Determine the sensitivity and specificity of these assays in assessing CA 15-3 in CSF.

        -  Assess favorability of intrathecal production of CA 15-3.

        -  Determine threshold interpretations of CA 15-3 levels in CSF.

      OUTLINE: This is a multicenter study.

      Within 15 days of suspected meningeal involvement, blood and cerebrospinal fluid samples are
      collected. Samples are examined by immunoenzyme assays. Patients with suspected cases of
      carcinomatous meningitis undergo cerebrospinal MRI.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Anticipated">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CA 15-3 levels in cerebrospinal fluid</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Meets 1 of the following criteria:

               -  Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous
                  meningitis, with or without brain metastasis

               -  Other type of cancer with evidence suggestive of carcinomatous meningitis

               -  Meningeal syndrome without context of cancer

        PATIENT CHARACTERISTICS:

          -  No other prior cancers

          -  Not pregnant or nursing

        PRIOR CONCURRENT THERAPY:

          -  No prior intrathecal treatment

          -  At least 4 weeks since prior interferon

          -  No concurrent participation in another clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Le Rhun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Le Rhun</last_name>
      <phone>33-32-029-5959</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2009</study_first_submitted>
  <study_first_submitted_qc>July 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2009</study_first_posted>
  <last_update_submitted>April 6, 2010</last_update_submitted>
  <last_update_submitted_qc>April 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2010</last_update_posted>
  <keyword>leptomeningeal metastases</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>tumors metastatic to brain</keyword>
  <keyword>adult meningioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

